Form 4: Guardant Health Co-CEO Reports Routine Stock Transactions

Guardant Health Co-CEO Helmy Eltoukhy reported recent acquisitions of common stock through RSU vesting and subsequent tax-related dispositions.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), reported changes in beneficial ownership of common stock.
• On September 30, 2025, 4,814 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently on September 30, 2025, 2,440 shares were disposed of at a price of $62.48 per share to cover tax withholding obligations related to the RSU vesting.
• On October 1, 2025, an additional 23,997 shares of common stock were acquired through the vesting of restricted stock units.
• On October 1, 2025, 12,162 shares were disposed of at a price of $62.65 per share to satisfy tax withholding obligations for the RSU vesting.
• Following these reported transactions, Mr. Eltoukhy beneficially owns 2,137,708 shares of Guardant Health common stock.
• The RSUs vesting on September 30, 2025, were part of an award granted on March 12, 2025, which vests in four equal installments on the last day of each calendar quarter.
• The RSUs vesting on October 1, 2025, were part of an award granted on March 18, 2024, with 33% vesting on January 1, 2025, and the remaining 67% vesting in equal quarterly installments over the subsequent two-year period.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation events (RSU vesting and tax-related share dispositions). This is a neutral to slightly positive indicator as it reflects ongoing executive retention and alignment of interests, but does not convey new material information about the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates continued equity compensation for the Co-CEO, aligning management's interests with shareholders.
• The transactions reflect standard executive compensation practices and retention mechanisms.

Negatives

• A portion of the vested shares was disposed of to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership for those specific shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of insider transactions, specifically related to executive compensation. It does not provide information directly related to broader industry trends or competitive landscape, but rather reflects standard practices for equity-based compensation within publicly traded companies.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation, which is a standard cost of doing business. The Co-CEO's continued equity ownership aligns his interests with those of shareholders.
• Employees: The filing highlights the company's use of equity compensation, which is a common practice for attracting and retaining key talent.

Next Steps

• Continued quarterly vesting of the restricted stock unit award granted on March 18, 2024, over the remaining two-year period.
• The final installment of the restricted stock unit award granted on March 12, 2025, is scheduled to vest on December 31, 2025.

Key Dates

Recommendation

This Form 4 filing details routine vesting of restricted stock units and subsequent tax-related share dispositions by a Co-CEO. Such transactions are standard for executive compensation and do not typically signal a change in company fundamentals or warrant a significant shift in investment strategy based solely on this report. Investors should consider broader company performance and market conditions.

Keywords

Guardant Health, GH, Helmy Eltoukhy, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Co-CEO, Director